Replies to post #204092 on Biotech Values

[mcbio]

QURE -

1) There is less natural anti-AAV5 antibody in general population (UniQure's) then there is for AAV8 (Sparks).

Ok I get it a bit better now. Regardless of how good ONCE treatment proves to be, it won't work in all patients and hopefully QURE can work in these. Doesn't matter if QURE treatment is a lot inferior as long as it works in those patients that ONCE treatment does not.

Any hard numbers out there on estimates of number of patients AAV5 vector could work in versus AAV8? Also, curious what competition looks like for QURE in hemophilia B with AAV5 vector specifically if you know.